Biomonitor Acquires the Irish Theranostic Company Neutekbio
News Dec 05, 2008
Biomonitor A/S has completed the acquisition of the Irish company Neutekbio Ltd. on 27 November 2008. Neutekbio's technologies and products complement Biomonitor’s current offerings to physicians and clinics involved in treatment of patients with Multiple Sclerosis, Rheumatoid Arthritis and Crohn’s disease worldwide.
Biomonitor will continue the R&D and manufacturing operations in Ireland and the ongoing collaboration with the French research institution CNRS in Paris. CNRS is a leading research organization in cell biology, virology, and medicine.
The acquisition is made possible by the financial support from Sunstone Capital in Denmark. "We are committed to supporting Biomonitor in becoming a leader in monitoring and improving costly protein based therapies - also by acquisition of supplementary products and technologies when possible", says Soren Lemonius, Chairman of Biomonitor and Partner in Sunstone Capital.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018